Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jun 19;10(6):e0130090.
doi: 10.1371/journal.pone.0130090. eCollection 2015.

A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients

Affiliations
Comparative Study

A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients

Charles E Rose et al. PLoS One. .

Abstract

HIV RNA viral load (VL) is a pivotal outcome variable in studies of HIV infected persons. We propose and investigate two frameworks for analyzing VL: (1) a single-measure VL (SMVL) per participant and (2) repeated measures of VL (RMVL) per participant. We compared these frameworks using a cohort of 720 HIV patients in care (4,679 post-enrollment VL measurements). The SMVL framework analyzes a single VL per participant, generally captured within a "window" of time. We analyzed three SMVL methods where the VL binary outcome is defined as suppressed or not suppressed. The omit-participant method uses a 8-month "window" (-6/+2 months) around month 24 to select the participant's VL closest to month 24 and removes participants from the analysis without a VL in the "window". The set-to-failure method expands on the omit-participant method by including participants without a VL within the "window" and analyzes them as not suppressed. The closest-VL method analyzes each participant's VL measurement closest to month 24. We investigated two RMVL methods: (1) repeat-binary classifies each VL measurement as suppressed or not suppressed and estimates the proportion of participants suppressed at month 24, and (2) repeat-continuous analyzes VL as a continuous variable to estimate the change in VL across time, and geometric mean (GM) VL and proportion of participants virally suppressed at month 24. Results indicated the RMVL methods have more precision than the SMVL methods, as evidenced by narrower confidence intervals for estimates of proportion suppressed and risk ratios (RR) comparing demographic strata. The repeat-continuous method had the most precision and provides more information than other considered methods. We generally recommend using the RMVL framework when there are repeated VL measurements per participant because it utilizes all available VL data, provides additional information, has more statistical power, and avoids the subjectivity of defining a "window."

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SG is an employee of ICF Macro International, a contractor to CDC, providing personnel support for data management and analysis. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. An example of log10(VL) copies/mL collected over time from baseline (month zero) and at subsequent follow-up visits for four participants.
The triangles and squares represent the closest VL to month 24 for each of the four participants.
Fig 2
Fig 2. The retention in care (RIC) study distribution of each participant’s closest VL copies/mL to month 24, where zero represents month 24.
There are 551 (76.5%) participants who have their closest VL within 6 months of month 24 and 232 (32.2%) whose closest VL is within 30 days.
Fig 3
Fig 3. Box plots by characteristic for the participants predicted VLs at month 24 and rate of change (slope).
The shaded box represents the 25th and 75th percentiles, while the vertical line and diamond within the shaded box are the median and mean, respectively. The upper and lower arms, represented by vertical lines, are the 2.5 and 97.5 percentiles, and dots outside these arms are considered outliers.
Fig 4
Fig 4. The predicted geometric mean (GM) by characteristic using the pdf-cdf random effects model plotted on the VL and log10(VL) scales.
The horizontal line is the defined level of suppression (<200 copies/mL).

References

    1. Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. A randomized double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonovir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013;65: e121–e124. - PubMed
    1. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double–blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricotabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 Infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1): 96–100. 10.1097/QAI.0b013e318289545c - DOI - PubMed
    1. Koenig L, Pals S, Palmore M, Stratford D, Ellerbrock T. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychology. 2008;27: 159–169. 10.1037/0278-6133.27.2.159 - DOI - PubMed
    1. Gill V, Lima V, Zhang W, Wynhoven B, Yip B, Hogg R, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clinical Infectious Diseases. 2010;50(2):98–105. - PMC - PubMed
    1. Moore R, Bartlett J. Dramatic decline in the HIV RNA level over calendar time in a large urban HIV practice. Clinical Infectious Diseases. 2011;53: 600–604. 10.1093/cid/cir467 - DOI - PMC - PubMed

Publication types